İdiopatik Parkinson Hastalığında Dürtüsellik: Eşleştirilmiş Vaka Kontrol Çalışması

Yıl 2020, Cilt: 9 Sayı: 2, 9 - 15, 31.08.2020

Mesude Tutuncu , Nazan Karagöz , Vasfiye Burcu Albay , Aysun Soysal

https://doi.org/10.47493/abantmedj.2020.1

Öz

GİRİŞ ve AMAÇ: Çalışmanın amacı İdiopatik parkinson hastalarında (IPH) dürtü kontrol bozukluğu (DKB) prevelansını saptamak ve dürtü kontrol bozukluğunun dürtüsellik üzerine etkisine bakmak.
YÖNTEM ve GEREÇLER: 40 IPH ve 40 sağlıklı kontrol dahil edildi. tüm katılımcılar Minnesota Dürtü Kontrol Bozukluğu testi ve Barret dürtüsellik ölçeği ile değerlendirildi
BULGULAR: 7 IPH ve 1 sağlıklı kontrolde dürtü kontrol bozukluğu saptandı. Dopamin agonist kullanımı DKB için risk oluşturuyordu. Hasta grupta motor dürtüslellik harici tüm dürtüsellik parametreleri daha fazlaydı. Hasta grupta kllinik olarak DKB varlığında motor dürtüsellik harici tüm dürtüsellik parametreleri artıyordu.
TARTIŞMA ve SONUÇ: IPD'deki motor olmayan bulgular sorgulanmadığı takdirde göz ardı edilebilir. İPD hastalarında artan dürtüsellik dikkatlice izlenmelidir. ICD'si olmayan IPD hastalarının bile, özellikle planlama dışı ve bilişsel alanlarda, dürtüsellik eğilimlerini arttırdığı unutulmamalıdır. Ayrıca, yalnızca motor dürtüsellik ölçen testler yeterli olmayabilir.

Anahtar Kelimeler

Parkinson Hastalığı, Dürtü Kontrol Bozuklukları, Dürtüsellik, Dopamin Agonisti, Dopamin Replasman Tedavisi

Impulsivity In Idiopathic Parkinson Disease: Paired Case Control Study

Öz

INTRODUCTION: The aim of the current study was to estimate the frequency of Impulse Control Disorder (ICD) in patients with Idiopathic Parkinson’s Disease (IPD) and to investigate impulsivity in IPD patients.
METHODS: 40 IPD patients (24 female, 16 male) treated with dopamine replacement therapy (DRT) and age and sex similar 40 healthy controls (HC) (23 female, 17 male) were included in this paired case-control study. Minnesota Impulsive Disorder Interview (MIDI) and the Turkish version of the Barratt Impulsiveness Scale (BIS-11) were applied to all participants. The patient and control groups were compared in terms of impulsivity and ICD. The effect of dopamine agonist (DA) usage on the presence of impulse control disorder was evaluated in the patient group.
RESULTS: 7 patients with IPD (17.5%) and 1 healthy control (2.5%) reported at least one ICD in MIDI. Multiple ICDs were reported in 2 of 7 patients (28.57%) with IPD.
ICD was significantly more frequent in IPD patient group (p=0.002) and DA was found to be a significant risk for ICD. IPD patients had higher scores in total impulsivity, non-planning, and cognitive impulsivity but interestingly lower scores in motor impulsivity as compared with controls. Except for motor impulsivity, the other domains of impulsivity including nonplanning and cognitive impulsivity were found to be increased in the presence of ICD in patients group.
DISCUSSION AND CONCLUSION: Non-motor findings in IPD can be overlooked if they are not questioned. Increased impulsivity should be carefully followed in patients with IPD. It should be kept in mind that even IPD patients who had no ICD have increased tendencies for impulsivity, especially in non-planning and cognitive areas. In addition, the tests which only measures motor impulsivity may not be sufficient.

Anahtar Kelimeler

Parkinson’s Disease, Impulse Control Disorders, Impulsiveness, Dopamine Agonist, Dopamine Replacement Therapy

Kaynakça

• Alvord EC Jr, Forno LS, Kusske JA, Kauffman RJ, Rhodes JS, Goetowski CR. The pathology of Parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv Neurol 1974; 5: 175-93.
• Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003; 18: 467–86.
• Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev 2006;30(1):1-23.
• Tang J, Strafella AP. The frontostriatal circuitry and behavioral complications in PD. Parkinsonism & related disorders 2012;18(1): 104-6.
• Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson’s disease. Mov Disord 2009;24: 1561–70.
• Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, et al. Mechanisms underlying dopamine mediated reward bias in compulsive behaviours. Neuron 2010;65: 135-42.
• Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, et al. Amantadine use associated with impulse control disorders in parkinson’s disease in cross-sectional study, Ann neurology 2010;68: 963-68.
• 1. “Psychiatric Aspects of Impulsivity”, Am J Psychiatry, 158, 1783-93.
• Avon AR, robbins TW, Poldrack RA. Inhibition and rifht inferior frontal cortex. Trneds Cogn Sci 2004;8: 170-177.
• Clark L. Decision making during gambling an integration of cognitive and psychobiological approaches Philos Trans R Soc Lond b Biol Sci2010; 365:319-30.
• Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson disease. Exp Brain Res 2004; 212:371-84.
• Fahn SE, RÜ; atmot UPsDRSD C. (1987) Unified Parkinsons Disease Ratting Scale In: Fahn SM, Calne D, editor. Recent developments in Parkinsons disease New York Macmillan pp 153-63.
• Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427–42.
• Folstein M, Folstein S, McHugh P. ‘Mini-mental state’: a practical methodfor, grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189e98.
• Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Disord 2010; 25:2649e53.
• Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry.2005;162:2184–88.
• Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology 1995; 51(6):768–74.
• Gulec H, Tamam L, Gulec MY et al. Psychometric properties of Turkish version of BIS-11. Klinik Psikofarmakoloji Bülteni 2008; 18:251-8.
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. (2010) 67:589–95.
• Maréchal E, Denoiseux B, Thys E, Crosiers D, Pickut B, Cras P. Impulse control disorders in Parkinson's disease: An overview from neurobiology to treatment. J Neurol 2015; 262:7-20.
• Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301–303.
• Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010 Mar;16(3):202-7.
• Garlovsky JK, Simpson J, Grünewald RA, Overton PG. Impulse control disorders in Parkinson’s disease: predominant role of psychological determinants. Psychol Health. 2016 Dec;31(12):1391-414.
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study J Neurol Neurosurg Psychiatry. 2014 Jan 16.
• Voon V, Hassan Dodd MI, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005; 62:1377–81.
• Kenangil G, Ozekmekci S, Sohtaoglu M, Erginoz E. Compulsive behaviors in patients with Parkinson’s disease. The neurologist 2010;16(3):192-5.
• Patton, J. H., Stanford, M. S., & Barratt, E. S. (1995). Factor structure of the Barratt impulsiveness scale. Journal of Clinical Psychology, 51(6), 768–74.
• Barratt ES, Stanford MS, Kent TA, et al. Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Biol Psychiatry. 1997;41(10):1045–61.
• Voon V, Hassan K, Zurowski M, Souza M De, Thomsen T, Fox S, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67(7):1254–7.
• Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, et al. Dopamine agonists and risk: impulse control disorders in Parkinson’s; disease. Brain. 2011;134(5):1438–46.
• Bokura H, Yamaguchi S, Kobayashi S. Event-related potentials for response inhibition in Parkinson’s disease. Neuropsychologia. 2005;43(6):967–75.
• Antonelli F, Strafella AP. Behavioral disorders in Parkinson’s disease: The role of dopamine. Parkinsonism Relat Disord. 2014;20: 10–2.
• Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple Modes of Impulsivity in Parkinson’s Disease. PLoS One. 2014;9(1):85747.
• Antonelli F, Ray N, Strafella AP. Impulsivity and Parkinson’s disease: More than just disinhibition. J Neurol Sci. 2011;310(1–2):202–7.
• van Belle J, Vink M, Durston S, Zandbelt BB. Common and unique neural networks for proactive and reactive response inhibition revealed by independent component analysis of functional MRI data. Neuroimage. 2014; 103:65–74.
• S Gauggel, M Rieger, T-A Feghoff, Inhibition of going responses in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75:539-44.
• Antonelli F, Ko JH, Miyasaki J, Lang AE, Houle S, Valzania F, et al. Dopamine-agonists and impulsivity in Parkinson’s disease: Impulsive choices vs. impulsive actions. Hum Brain Mapp. 2014;35(6):2499–506.
• Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinsons disease. CNS Drugs. 2010;24(11):941–68.
• Aron A. From Reactive to Proactive and Selective Control: Developing a Richer Model for Stopping Inappropriate Responses. Biol Psychiatry. 2011;69(12): e55–68.
• Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, et al. (2005) The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30: 1724–34.
• Macoveanu J, Rowe JB, Hornboll B, Elliott R, Paulson OB, et al. (2012) Playing it safe but losing anyway-Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur Neuropsychopharmacol.
• Eagle DM, Bari A, Robbins TW (2008) The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) 199: 439–56.
• Schultz W (2001) Reward signaling by dopamine neurons. Neuroscientist 7: 293–302.